Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 October 2025 | Story André Damons | Photo André Damons
Nuclear Medicine
Smiling proudly are Dr Gerrit Engelbrecht, Head of the UFS Department of Nuclear Medicine, Dr Tebatso Tebeila, senior resident in the same department, and Prof Osayande Evbuomwan, Senior Lecturer and medical specialist in nuclear medicine in the Department of Nuclear Medicine, with the certificate indicating they are now a Clinical Theranostics Centre of Excellence.

The Department of Nuclear Medicine at the Universitas Academic Hospital (UAH) and the University of the Free State (UFS) have been certified as Clinical Theranostics Centers of Excellence from the International Centers for Precision Oncology Foundation (ICPO). The hospital now joins only two other centres in South Africa to achieve this prestigious recognition.

The certification followed a rigorous evaluation process by the ICPO Foundation, which assessed the department’s clinical standards, infrastructure, expertise, and commitment to advancing theranostics. The application and verification process was done by Dr Tebatso Tebeila, a senior resident at the department who has just passed her final exams. She was supported by Dr Gerrit Engelbrecht, Head of the UFS Department of Nuclear Medicine, in the process which included interviews with the ICPO accreditation and projects director Dr Marwa Hakkam. Dr Tebeila had also completed the ICPO short course in Radiomolecular Precision Oncology through the ICPO Academy of Theranostics.

The UAH Nuclear Medicine Department began theranostics activities about five years ago, particularly in neuroendocrine and prostate malignancies. Prof Osayande Evbuomwan, Senior Lecturer and medical specialist in nuclear medicine in the UFS Department of Nuclear Medicine, received training for this during his residency period and had completed a rigorous international training workshop organised by the International Atomic Energy Agency on theranostics, particularly in prostate cancer, neuroendocrine neoplasms and well differentiated thyroid cancer. Prof Evbuomwan passed all these training and skills down to the department. The certification was further strengthened by the installation of department’s new state-of-the-art digital PET/CT camera, placing it on par with similar academic departments in the country. The recognition was officially conferred during the ICPO Reception at the European Association of Nuclear Medicine Congress in Barcelona earlier this month.  

 

A milestone achievement

“Being granted this certification signifies international recognition of our hospital’s commitment to the highest clinical, academic, and ethical standards in theranostics. It confirms that our institution meets the global benchmarks for delivering precision oncology care that integrates diagnostics and therapy for personalised cancer management.

“For our department and the University of the Free State, this is a milestone achievement that highlights our leadership in nuclear medicine and molecular imaging. It strengthens our research and training capacity and also attracts residents who want to be trained in nuclear medicine. It also enhances collaboration with international partners and aligns with our mission to advance precision medicine in South Africa and beyond,” says Prof Evbuomwan.

Theranostics, he explains, is an aspect of nuclear medicine that involves the use of a tracer bound to a radioisotope that can specifically locate and image cancer cells with high precision, characterise them and determine how much radiation will get to them. Using the same tracer, but a different radioisotope for therapy, these cancer cells are targeted with high precision and destroyed. It could be so precise that it targets only the cancer, sparing most of the normal tissue and thus resulting in less serious side effects. It is an aspect of nuclear medicine that is bound to revolutionise cancer care.

Dr Gerrit Engelbrecht says as a department, they are honoured and deeply proud of this achievement as it reflects months of dedication, innovation, and teamwork. “It validates our commitment to excellence in improving patient care and academic advancement, and we are motivated to build on this success. We are also grateful to Dr Tebeila for her initiative, hard work, dedication and networking skills.

“We would like to thank the ICPO Foundation for this recognition and for its continued efforts to support theranostics in developing regions. We also acknowledge the hard work of our staff, and partners who made this possible. This milestone inspires us to continue driving innovation and equitable access to precision oncology in Bloemfontein, the Free State province and South Africa at large.”

 

Forefront of precision oncology 

According to Prof Evbuomwan, patients will also benefit from this certification as it translates to improved access to world-class, and evidence-based theranostic management. It means earlier diagnosis, more accurate therapy selection, and ultimately, better treatment outcomes and quality of life for those with some of these cancers. They strongly believe the patients in the Free State also deserve access to this management, as the world is now moving slowly into the era of personalised and precision medicine. The Universitas Academic Hospital is now among three centres in South Africa (Numeri in SBAH Pretoria and Umhlanga Molecular Imaging and Therapy Centre in Durban) to achieve this prestigious recognition, joining an international network of 46 centres, mostly located in low- and middle-income countries. This positions the UFS at the forefront of precision oncology on the African continent.

Prof Evbuomwan says they hope to use this new status to expand patient access to theranostic treatments, foster multidisciplinary collaborations within the Universitas academic circuit, and participate in global research initiatives through the ICPO Academy for Theranostics. Certifications like this, he continues, would also help to attract more staff and junior resident doctors to the facility. It will also help them train the next generation of nuclear medicine specialists and strengthen South Africa’s role in precision oncology. The ICPO will also offer direct assistance to the facility to achieve these objectives.

On her trip to the EANM Congress in Barcelona to receive the certificate and to attend the international congress, Dr Tebeila said it is always such an honour to attend international conferences and this year’s EANM was particularly invigorating with the latest scientific presentations in various theranostic applications by peers and well-known experts in the global nuclear medicine sphere. 

“The highlight was, of course, attending the annual Oncidium Foundation Ambassadors meeting and being part of the ICPO certification ceremony along with my counterparts from 23 other centres spanning Asia, Arab regions and Africa. 

“My wish is to see the UAH nuclear medicine department grow in leaps and bounds, epically in patient reach, clinical research with academic expansion and overall excellence in service delivery. This ICPO theranostics centre of excellence certification is only the beginning of what is to come.”

News Archive

Inaugural lecture: Prof Robert Bragg, Dept. of Microbial, Biochemical and Food Biotechnology
2006-05-17



Attending the inaugural lecture were in front from the left Prof Robert Bragg (lecturer at the Department of Microbial, Biochemical and Food Biotechnology) and Frederick Fourie (Rector and Vice-Chancellor).  At the back from the left were Prof James du Preez (Departmental Chairperson:  Department of Microbial, Biochemical and Food Biotechnology) and Prof Herman van Schalkwyk (Dean: Faculty of Natural and Agricultural Sciences). Photo: Stephen Collett
 

A summary of an inaugural lecture delivered by Prof Robert Bragg at the University of the Free State:

CONTROL OF INFECTIOUS AVIAN DISEASES – LESSONS FOR MAN?

Prof Robert R Bragg
Department of Microbial, Biochemical and Food Biotechnology
University of the Free State

“Many of the lessons learnt in disease control in poultry will have application on human medicine,” said Prof Robert Bragg, lecturer at the University of the Free State’s (UFS) Department of Microbial, Biochemical and Food Biotechnology during his inaugural lecture.

Prof Bragg said the development of vaccines remains the main stay of disease control in humans as well as in avian species.  Disease control can not rely on vaccination alone and other disease-control options must be examined.  

“With the increasing problems of antibiotic resistance, the use of disinfection and bio security are becoming more important,” he said.

“Avian influenza (AI) is an example of a disease which can spread from birds to humans.  Hopefully this virus will not develop human to human transmission,” said Prof Bragg.

According to Prof Bragg, South Africa is not on the migration route of water birds, which are the main transmitters of AI.  “This makes South Africa one of the countries less likely to get the disease,” he said.

If the AI virus does develop human to human transmission, it could make the 1918 flu pandemic pale into insignificance.  During the 1918 flu pandemic, the virus had a mortality rate of only 3%, yet more than 50 million people died.

Although the AI virus has not developed human-to-human transmission, all human cases have been related to direct contact with infected birds. The mortality rate in humans who have contracted this virus is 67%.

“Apart from the obvious fears for the human population, this virus is a very serious poultry pathogen and can cause 100% mortality in poultry populations.  Poultry meat and egg production is the staple protein source in most countries around the world. The virus is currently devastating the poultry industry world-wide,” said Prof Bragg.

Prof Bragg’s research activities on avian diseases started off with the investigation of diseases in poultry.  “The average life cycle of a broiler chicken is 42 days.  After this short time, they are slaughtered.  As a result of the short generation time in poultry, one can observe changes in microbial populations as a result of the use of vaccines, antibiotics and disinfectants,” said Prof Bragg.   

“Much of my research effort has been directed towards the control of infectious coryza in layers, which is caused by the bacterium Avibacterium paragallinarum.  This disease is a type of sinusitis in the layer chickens and can cause a drop in egg product of up to 40%,” said Prof Bragg.

The vaccines used around the world in an attempt to control this disease are all inactivated vaccines. One of the most important points is the selection of the correct strains of the bacterium to use in the vaccine.

Prof Bragg established that in South Africa, there are four different serovars of the bacterium and one of these, the serovar C-3 strain, was believed to be unique to Southern Africa. He also recently discovered this serovar for the first time in Israel, thus indicating that this serovar might have a wider distribution than originally believed.

Vaccines used in this country did not contain this serovar.  Prof Bragg established that the long term use of vaccines not containing the local South African strain resulted in a shift in the population distribution of the pathogen.

Prof Bragg’s research activities also include disease control in parrots and pigeons.   “One of the main research projects in my group is on the disease in parrots caused by the circovirus Beak and Feather Disease virus. This virus causes serious problems in the parrot breeding industry in this country. This virus is also threatening the highly endangered and endemic Cape Parrot,” said Prof Bragg.

Prof Bragg’s research group is currently working on the development of a DNA vaccine which will assist in the control of the disease, not only in the parrot breeding industry, but also to help the highly endangered Cape Parrot in its battle for survival.

“Not all of our research efforts are directed towards infectious coryza or the Beak and Feather Disease virus.  One of my Masters students is currently investigating the cell receptors involved in the binding of Newcastle Disease virus to cancerous cells and normal cells of humans. This work will also eventually lead to a possible treatment of cancer in humans and will assist with the development of a recombinant vaccine for Newcastle disease virus,” said Prof Bragg.

We are also currently investigating an “unknown” virus which causes disease problems in poultry in the Western Cape,” said Prof Bragg.
 
“Although disinfection has been extensively used in the poultry industry, it has only been done at the pre-placement stage. In other words, disinfectants are used before the birds are placed into the house. Once the birds are placed, all use of disinfectants stops,” said Prof Bragg.

“Disinfection and bio security can be seen as the ‘Cinderella’ of disease control in poultry.  This is also true for human medicine. One just has to look at the high numbers of people who die from hospital-acquired infections to realise that disinfection is not a concept which is really clear in human health care,” said Prof Bragg.

Much research has been done in the control of diseases through vaccination and through the use of antibiotics. “These pillars of disease control are, however, starting to crumble and more effort is needed on disinfection and bio security,” said Prof Bragg.

Prof Bragg has been working in close co-operation with a chemical manufacturing company in Stellenbosch to develop a unique disinfectant which his highly effective yet not toxic to the birds.

As a result of this unique product, he has developed the continual disinfection program for use in poultry. In this program the disinfectant is used throughout the production cycle of the birds. It is also used to ensure that there is excellent pre-placement disinfection.

“The program is extensively used for the control of infectious diseases in the parrot-breeding industry in South Africa and the product has been registered in 15 countries around the world with registration in the USA in the final process,” said Prof Bragg.

“Although the problem of plasmid mediated resistance to disinfectants is starting to rear its ugly head, this has allowed for the opening of a new research field which my group will hopefully exploit in the near future,” he said.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept